Gilead Reports Third-Quarter Revenue of $8.3 Billion
Valid market news retained in the public archive without immediate LiveCast distribution.
Story updates
08:05:19 PM UTC
SquawkNews
By Mackenzie TatananniGilead Sciences' latest earnings show the drugmaker continues to benefit from relentless demand for its core HIV drug portfolio, even as other parts of the business falter.Third-quarter sales climbed 13% to $8.3 billion from the year-ago period, handily surpassing Wall Street'…